Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AnaptysBio, Inc. (ANAB : NSDQ)
 
 • Company Description   
AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

Number of Employees: 102

 
 • Price / Volume Information   
Yesterday's Closing Price: $20.88 Daily Weekly Monthly
20 Day Moving Average: 476,832 shares
Shares Outstanding: 28.19 (millions)
Market Capitalization: $588.53 (millions)
Beta: 0.17
52 Week High: $37.89
52 Week Low: $19.79
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -5.56% 3.40%
12 Week -33.57% -25.34%
Year To Date -39.91% -26.59%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10770 WATERIDGE CIRCLE SUITE 210
-
SAN DIEGO,CA 92121
USA
ph: 858-362-6295
fax: -
investors@anaptysbio.com http://www.anaptysbio.com
 
 • General Corporate Information   
Officers
Hamza Suria - Chief Executive Officer and President
Dennis Mulroy - Chief Financial Officer
Daniel Faga - Director
Dennis Fenton - Director
Laura J. Hamill - Director

Peer Information
AnaptysBio, Inc. (CORR.)
AnaptysBio, Inc. (RSPI)
AnaptysBio, Inc. (CGXP)
AnaptysBio, Inc. (BGEN)
AnaptysBio, Inc. (GTBP)
AnaptysBio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 032724106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 28.19
Most Recent Split Date: (:1)
Beta: 0.17
Market Capitalization: $588.53 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.95 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-4.26 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.78
Price/Cash Flow: -
Price / Sales: 11.13
EPS Growth
vs. Year Ago Period: -98.48%
vs. Previous Quarter: -15.93%
Sales Growth
vs. Year Ago Period: -91.38%
vs. Previous Quarter: -4.06%
ROE
03/31/22 - -20.44
12/31/21 - -14.95
09/30/21 - 2.17
ROA
03/31/22 - -14.05
12/31/21 - -11.92
09/30/21 - 2.02
Current Ratio
03/31/22 - 25.90
12/31/21 - 34.40
09/30/21 - 18.51
Quick Ratio
03/31/22 - 25.90
12/31/21 - 34.40
09/30/21 - 18.51
Operating Margin
03/31/22 - -140.72
12/31/21 - -89.19
09/30/21 - 6.87
Net Margin
03/31/22 - -143.46
12/31/21 - -91.49
09/30/21 - 6.87
Pre-Tax Margin
03/31/22 - -143.46
12/31/21 - -91.49
09/30/21 - 6.87
Book Value
03/31/22 - 11.73
12/31/21 - 12.89
09/30/21 - 13.98
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 0.00
12/31/21 - 0.00
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©